Calliditas Therapeutics (CALT) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
At the annual general meeting of Calliditas Therapeutics, key resolutions included the adoption of financial statements for 2023, re-election of board members and auditors, and the decision to not distribute dividends for the year. Additionally, the company was authorized to issue new shares, warrants, and/or convertibles up to 20% of the total shares, and to transfer its own shares, to increase financial and operational flexibility. The meeting also approved new long-term incentive programs for board members and key personnel, and updated remuneration guidelines for group management.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.